$110.42
2.29% (Daily)
Market Cap
$27.71B
Revenue
$3.15B
Rank by MCap
#1046
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ugur Sahin M.D.
Headquarters
Mainz
Employees
6,772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical ...
Loading chart…